---
title: "CanSino Biologics Wins PIC/S GMP Nod for Key Conjugate Vaccines"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277909067.md"
description: "CanSino Biologics, Inc. has received a Good Manufacturing Practice (GMP) certificate from the Pharmaceutical Inspection Co-Operation Scheme for its ACYW135 meningococcal and 13-valent pneumococcal conjugate vaccines. This certification, following an inspection by Malaysia’s National Pharmaceutical Regulatory Agency, confirms compliance with PIC/S standards, aiding in the registration and marketing of the vaccines in Malaysia and other member jurisdictions. This milestone enhances CanSino's competitive position in the global vaccine market. The current analyst rating for CanSino's stock (HK:6185) is a Hold with a price target of HK$39.00."
datetime: "2026-03-05T09:10:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277909067.md)
  - [en](https://longbridge.com/en/news/277909067.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277909067.md)
---

# CanSino Biologics Wins PIC/S GMP Nod for Key Conjugate Vaccines

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

CanSino Biologics, Inc. Class H ( (HK:6185) ) has shared an announcement.

CanSino Biologics Inc. has obtained a Good Manufacturing Practice certificate under the Pharmaceutical Inspection Co-Operation Scheme for the manufacturing site of its ACYW135 meningococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine. The certification follows a compliance inspection by Malaysia’s National Pharmaceutical Regulatory Agency and confirms that the company’s manufacturing and quality systems meet PIC/S standards.

The PIC/S GMP recognition is expected to facilitate registration and marketing of the two vaccines in Malaysia and other member jurisdictions that mutually recognize such inspections. This regulatory milestone strengthens CanSino Biologics’ ability to expand its vaccine portfolio in international markets and may enhance its competitive positioning among global vaccine manufacturers, while investors are reminded to remain cautious when trading the company’s shares.

The most recent analyst rating on (HK:6185) stock is a Hold with a HK$39.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.

**More about CanSino Biologics, Inc. Class H**

CanSino Biologics Inc. is a China-based biopharmaceutical company specializing in the research, development and manufacturing of innovative vaccines. The company focuses on conjugate and other advanced vaccines for infectious diseases, targeting both domestic and international markets, including emerging regulatory jurisdictions in Asia and other PIC/S member countries.

**Average Trading Volume:** 928,733

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$13.15B

### Related Stocks

- [06185.HK](https://longbridge.com/en/quote/06185.HK.md)

## Related News & Research

- [CanSinoBIO: From Profit Turnaround to Value Realization as an Innovative Vaccine Leader](https://longbridge.com/en/news/281103901.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [FDA drug center head fired after commissioner's exit](https://longbridge.com/en/news/286647070.md)
- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [Investeringsforeningen Nykredit Invest Balance suspender handel med udvalgte afdelinger](https://longbridge.com/en/news/286877547.md)